Clinical Trials Logo

Clinical Trial Summary

Canadians fear loss of vision more than any other disability. Vision loss has an enormous impact on quality-of-life and is extremely costly from a societal and economic perspective. In 2001, more than 600,000 Canadians were estimated to have severe vision loss, accounting for 17% of total disability in Canada. One in 9 individuals experience severe vision loss by 65 years of age; however, this increases to 1 in 4 individuals by 75 years. The financial cost of vision loss in Canada is $15.8 billion per year. There is a general perception that vision loss is "normal with aging" but 75% of vision loss is estimated to be preventable. The major causes of severe vision loss are age-related macular degeneration (ARMD), glaucoma, particularly primary open-angle glaucoma (POAG), and diabetic retinopathy (DR). Canada is headed for an epidemic of age-related eye disease and, unless something is done to prepare for this, severe vision loss will have significant consequences in terms of societal and economic costs. Through this proposed Research Program, and in conjunction with our international academic and private sector partners, we will build and develop unique quantitative imaging technologies to permit non-invasive assessment of visual changes, structural changes in the thickness of the retina at the back of the eye and also changes in the amount of blood flowing through the blood vessels that feed the retina with oxygen. This research will add to our basic knowledge in predicting the development of sight-threatening change in patients with the three diseases, and facilitate earlier detection of the problem to help us discover earlier treatments for people with these conditions. The reliability of each imaging technology will be assessed by determining its ability to differentiate between diseased and healthy eyes. Cross-sectional analyses at yearly intervals, as well as change over time analyses, will be undertaken.


Clinical Trial Description

There are a number of major steps that are required prior to the utilisation of these technologies in a clinical setting. This phase of the Proposal will aim to validate and calibrate the new technologies, explore the signal-to-noise ratio of RBF and oxygen saturation parameters, generate values to define the impact of absorption, morphological fundus variation and pre-retinal autofluorescence on oxygen saturation imaging and will establish a database of healthy control imaging values for both new technologies and the reproducibility of those measurements. Note: Sample size calculations have been conducted for all aspects of this phase of the protocol, based upon our extensive retinal vascular reactivity work. We will build and develop unique quantitative imaging technologies to that will permit us to explore the physiology of retinal and choroidal perfusion and vascular regulation, and retinal oxygenation.

Having completed the Validation and Calibration phase, this research will ultimately add to our basic knowledge in predicting the development of sight-threatening change in patients with the ARMD, diabetic retinopathy and primary open glaucoma, and facilitate earlier detection of the problem to help us discover earlier treatments for people with these conditions. The reliability of each imaging technology will be assessed by determining its ability to differentiate between diseased and healthy eyes. Through this proposed Research Program, we will build and develop unique quantitative imaging technologies to: Comprehensively assess the blood supply to, and vascular regulation characteristics of the posterior segment of the eye, a diagnostic capability that is currently severely limited. Assess oxygen saturation disturbances in the retina and ON that occur prior to clinically detectable changes, diagnostic capability that currently does not exist. Using the retinal blood supply and oxygen saturation parameters, we will derive net oxygen delivery to the retina and optic nerve head (ONH), a diagnostic capability that does not exist ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01348633
Study type Observational
Source University of Toronto
Contact Chris Hudson, Ph.D
Phone 416 603 5694
Email chudson@uwaterloo.ca
Status Recruiting
Phase N/A
Start date March 2012
Completion date August 2015

See also
  Status Clinical Trial Phase
Completed NCT01969708 - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Completed NCT03981549 - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Phase 1/Phase 2
Completed NCT02274259 - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Phase 4
Completed NCT01360385 - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab N/A
Not yet recruiting NCT00383773 - Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion N/A
Completed NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion N/A
Recruiting NCT04601701 - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Withdrawn NCT03417401 - Surgical Stabilizer Assisted RVC With rtPA for CRVO Phase 1
Completed NCT01976312 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Phase 3
Completed NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Phase 1/Phase 2
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Active, not recruiting NCT01011374 - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion Phase 1
Completed NCT03223714 - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Phase 3
Recruiting NCT01827722 - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Phase 4
Completed NCT00906685 - Bevacizumab for Central Retinal Vein Occlusion Study Phase 3
Active, not recruiting NCT04793100 - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections N/A
Recruiting NCT02405741 - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Phase 2